Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18549790 | 0.97 | S1PR5 (0.49) | S1PR5PRMT5EGFRS1PR1S1PR3 | |
| SCHEMBL18550375 | 0.88 | S1PR5 (0.61) | S1PR5EGFRS1PR1S1PR3WDR5 | |
| SCHEMBL18550311 | 0.88 | S1PR5 (0.47) | S1PR5PRMT5EGFRS1PR1S1PR3 | |
| SCHEMBL18549823 | 0.85 | S1PR5 (0.49) | S1PR5PRMT5EGFRS1PR1S1PR3 | |
| SCHEMBL18550364 | 0.85 | S1PR5 (0.59) | S1PR5EGFRS1PR1S1PR3WDR5 | |
| SCHEMBL18549943 | 0.81 | S1PR5 (0.45) | S1PR5PRMT5EGFRS1PR1 | |
| SCHEMBL18550250 | 0.80 | S1PR5 (0.52) | S1PR5S1PR1S1PR3 | |
| SCHEMBL18550450 | 0.80 | S1PR5 (0.46) | S1PR5PRMT5EGFRS1PR1S1PR3 | |
| SCHEMBL18550004 | 0.79 | S1PR5 (0.51) | S1PR5S1PR1S1PR3 | |
| SCHEMBL18550387 | 0.77 | S1PR5 (0.46) | S1PR5S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | S1PR5 4/4885PRMT5 2839/4885EGFR 3193/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | S1PR5 4/4885PRMT5 2839/4885EGFR 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.